HEIDELBERG, Germany (AP) — HEIDELBERG, Germany (AP) — Affimed N.V. (AFMD) on Tuesday reported a loss of $26.5 million in its third quarter.
The Heidelberg, Germany-based company said it had a loss of 17 cents per share.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.
The drug developer posted revenue of $2.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $1.8 million.
The company's shares closed at 33 cents. A year ago, they were trading at $2.17.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AFMD at https://www.zacks.com/ap/AFMD